approval
saveCOMETRIQ (CABOZANTINIB S-MALATE) — FDA approval
community read0 votes
Sponsor: EXELIXIS. Form: CAPSULE. Route: ORAL
view source ↗Data sources
last refreshed 5mo ago
Found something off?
drug timeline · 8
- phase 1 completionTakeda Pharmaceutical Co Ltd — Cabometyx (Phase I Trial Completion)Apr 30, 2026 · 154d ago
- approvalCOMETRIQ (CABOZANTINIB S-MALATE) — FDA approvalOct 9, 2025 · 357d ago
- approvalCABOMETYX (CABOZANTINIB S-MALATE) — FDA approvalOct 9, 2025 · 357d ago
- approvalCABOMETYX (CABOZANTINIB S-MALATE) — FDA approvalSep 10, 2025 · 386d ago
- approvalCABOMETYX (CABOZANTINIB S-MALATE) — FDA approvalMar 26, 2025 · 554d ago
- approvalCABOMETYX (CABOZANTINIB S-MALATE) — FDA approvalSep 20, 2023 · 1107d ago
- approvalCOMETRIQ (CABOZANTINIB S-MALATE) — FDA approvalAug 23, 2023 · 1135d ago
- approvalCABOMETYX (CABOZANTINIB S-MALATE) — FDA approvalFeb 13, 2023 · 1326d ago
🐶 often sniffed alongside
top 8- drugCABOMETYX97 co-mentions · 25 sources
- drugCOMETRIQ97 co-mentions · 25 sources
- tagApproval96 co-mentions · 24 sources
- drugcabozantinib48 co-mentions · 24 sources
- tagSmall Molecule48 co-mentions · 24 sources
- tagOncology2 co-mentions · 1 sources
- company$TAKTAKEDA PHARMACEUTICAL CO LTD1 co-mentions · 1 sources
- company$TKPHFTAKEDA PHARMACEUTICAL CO LTD1 co-mentions · 1 sources
comments(0)
5-min edit window · permanent after that